---
schema_version: "secwatch.filing_event.v1"
accession: "0001757073-22-000064"
form_type: "8-K"
ticker: "NVST"
cik: "0001757073"
company_name: "Envista Holdings Corp"
filed_at: "2022-05-17T23:59:59+00:00"
generated_at: "2026-06-25T12:20:48.720677+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Envista to acquire Osteogenics Biomedical for ~$30M annual sales; closes Q3

## Summary
- Definitive agreement to acquire Osteogenics Biomedical, Allotech, OBI Biologics (Cytoplast brand).
- Osteogenics has ~$30M annual sales; leader in regenerative solutions for dental bone grafting.
- Transaction subject to customary regulatory approvals; expected close in Q3 2022.
- No financing condition or shareholder vote required; funded from existing resources.

## SEC filing metadata
- accession: 0001757073-22-000064
- form_type: 8-K
- ticker: NVST
- cik: 0001757073
- company_name: Envista Holdings Corp
- filed_at: 2022-05-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757073/000175707322000064/0001757073-22-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757073/000175707322000064/nvst-20220517.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001757073-22-000064
- JSON: https://secwatch.observer/filing/0001757073-22-000064.json
- Plain text: https://secwatch.observer/filing/0001757073-22-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.